Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice

Reichert J and Pavolu A (2004). Monoclonal antibodies market. Nat Rev Drug Discov 3: 383–384

Paul WE (2003). Fundamental immunology. Lippincott Williams & Wilkins, Philadelphia

Waldmann TA and Strober W (1969). Metabolism of immunoglobulins. Prog Allergy 13: 1–110

Brambell FW, Hemmings WA and Morris IG (1964). A Theoretical Model of Gamma-Globulin Catabolism. Nature 203: 1352–1354

Jones EA and Waldmann TA (1972). The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51: 2916–2927

Rodewald R (1973). Intestinal transport of antibodies in the newborn rat. J Cell Biol 58: 189–211

Raghavan M and Bjorkman PJ (1996). Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12: 181–220

Rodewald R (1976). pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 71: 666–669

Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y and Ward ES (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26: 690–696

Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D and Simister NE (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89: 573–578

Junghans RP and Anderson CL (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93: 5512–5516

Dall’ Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA and Langermann S (2002). Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169: 5171–5180

Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ and Ward ES (1997). Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15: 637–640

Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, Ghetie V and Ward ES (1998). Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol 10: 1289–1298

Ghetie V and Ward ES (1997). FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592–598

Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A and Simister NE (1997). Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92: 69–74

Baxter LT, Zhu H, Mackensen DG and Jain RK (1994). Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54: 1517–1528

Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS and Lencer WI (1999). Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104: 903–911

Lobo ED, Hansen RJ and Balthasar JP (2004). Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645–2668

Tang L, Persky AM, Hochhaus G and Meibohm B (2004). Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184–2204

Covell DG, Barbet J, Holton OD, Black CD, Parker RJ and Weinstein JN (1986). Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Cancer Res 46: 3969–3978

Baxter LT, Zhu H, Mackensen DG, Butler WF and Jain RK (1995). Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55: 4611–4622

Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL and Jain RK (2002). Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4: 449–463

Ismail M, Abd-Elsalam MA and Al-Ahaidib MS (1998). Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB’)2 and F(AB) of the antivenin. Toxicon 36: 93–114

Zhu H, Baxter LT and Jain RK (1997). Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 38: 731–741

Zhu H, Melder RJ, Baxter LT and Jain RK (1996). Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res 56: 3771–3781

Varner JA, Nakada MT, Jordan RE and Coller BS (1999). Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3: 53–60

Jensenius JC and Williams AF (1974). The binding of anti-immunoglobulin antibodies to rat thymocytes and thoracic duct lymphocytes. Eur J Immunol 4: 91–97

Hansen RJ and Balthasar JP (2002). Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. [see comment]. Thromb Haemost 88: 898–899

Bailer AJ (1998). Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303–309

Nedelman JR, Gibiansky E and Lau DT (1995). Applying Bailer’s method for AUC confidence intervals to sparse sampling. Pharm Res 12: 124–128

Motulsky H (1995). Intuitive biostatistics. Oxford University Press, New York

Antohe F, Radulescu L, Gafencu A, Ghetie V and Simionescu M (2001). Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62: 93–105

McCarthy KM, Lam M, Subramanian L, Shakya R, Wu Z, Newton EE and Simister NE (2001). Effects of mutations in potential phosphorylation sites on transcytosis of FcRn. J Cell Sci 114: 1591–1598

Praetor A, Ellinger I and Hunziker W (1999). Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells. J Cell Sci 112(Pt 14): 2291–2299

Rojas R and Apodaca G (2002). Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol 3: 944–955

Raghavan M, Chen MY, Gastinel LN and Bjorkman PJ (1994). Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1: 303–315

Ward ES, Zhou J, Ghetie V and Ober RJ (2003). Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15: 187–195

Ghetie V and Ward ES (2002). Transcytosis and catabolism of antibody. Immunol Res 25: 97–113

Flessner MF, Lofthouse J and Zakaria ER (1997). In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273: H2783–2793

Hansen RJ and Balthasar JP (2003). Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92: 1206–1215

Brown RP, Delp MD, Lindstedt SL, Rhomberg LR and Beliles RP (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407–484

Gerlowski LE and Jain RK (1983). Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72: 1103–1127

Hahnfeldt P, Panigrahy D, Folkman J and Hlatky L (1999). Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59: 4770–4775

Predescu D and Palade GE (1993). Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. Am J Physiol 265: H725–733

Zhou J, Johnson JE, Ghetie V, Ober RJ and Sally Ward E (2003). Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol 332: 901–913

Hamby DM (1995). A comparison of sensitivity analysis techniques. Health Phys 68: 195–204

D’Argenio DZ and Schumitzky A (1997). ADAPT II User’s Guide: Pharmacokinetic/Pharmacodynamic systems analysis software. Biomedical Simulation Resource, Los Angeles

Ober RJ, Radu CG, Ghetie V and Ward ES (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551–1559

Braeckman R (2000). Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid, R (eds) Peptide and protein drug analysis, pp 633–669. Marcel Dekker, New York, NY

Henderson LA, Baynes JW and Thorpe SR (1982). Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 215: 1–11

Wright A, Sato Y, Okada T, Chang K, Endo T and Morrison S (2000). In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10: 1347–1355

Ferl GZ, Kenanova V, Wu AM and DiStefano JJ III (2006). A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5: 1550–1558

Ferl GZ, Wu AM and DiStefano JJ III (2005). A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33: 1640–1652

Blumberg RS, Koss T, Story CM, Barisani D, Polischuk J, Lipin A, Pablo L, Green R and Simister NE (1995). A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 95: 2397–2402

Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS and Lencer WI (2002). Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. [erratum appears in J Exp Med. 2003 Jun 2;197(11):1601]. J Exp Med 196: 303–310

Haymann JP, Levraud JP, Bouet S, Kappes V, Hagege J, Nguyen G, Xu Y, Rondeau E and Sraer JD (2000). Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11: 632–639

Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C and Tomino Y (2002). FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 282: F358–365

McFarlane AS (1963). Catabolism of plasma proteins. Lancet 1: 131–132